Drug intelligence / Profile preview

STM11315

Development stage: Unknown
Lead developer: STORM Therapeutics
Modality: Small Molecules

Overview

**STM11315** is a small molecule inhibitor targeting DHX9, an RNA helicase involved in RNA processing and implicated in cancer. It demonstrates compelling single-agent anti-tumor activity in preclinical models, achieving complete and durable tumor regression. Developed through discovery efforts likely associated with STORM Therapeutics' RNA-modifying enzyme platform, it represents a novel approach to oncology by modulating RNA biology to inhibit tumor growth.[11]

Targets

DHX9 (DEAH-box helicase 9)

Beyond the preview

Go deeper on STM11315.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STM11315.

Explore the full profile